A groundbreaking discovery from Cold Spring Harbor Laboratory (CSHL) promises to reshape the therapeutic landscape for estrogen receptor-positive (ER+) breast cancer, a disease subtype constituting approximately 75% of breast cancer cases globally. Despite the widespread use of
English (US) ·